New drug duo shows promise against hard-to-treat lung cancer
NCT ID NCT05009836
First seen Jun 12, 2026 · Last updated Jun 12, 2026
Summary
This study tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR mutation with MET amplification) live longer without their cancer growing. About 412 adults with incurable, advanced non-small cell lung cancer will receive either the drug combo or a placebo plus osimertinib. The goal is to see if the combination improves progression-free survival and is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong General Hospital
Guangzhou, China
Conditions
Explore the condition pages connected to this study.